Cellectis

Cellectis is a global, clinical-stage biopharmaceutical company. As pioneers and innovators in our field, we are driven by a single mission: to develop breakthrough treatments for patients with unmet medical needs.

With 26 years of expertise, we operate a best-in-class genome editing platform focused on immuno-oncology and gene therapy. By leveraging our proprietary gene-editing technologies, we engineer allogeneic CAR-T cells designed to recognize and eliminate cancer cells.

Currently, our two lead clinical programs are evaluating therapies for B-cell acute lymphoblastic leukemia (B-ALL) and non-Hodgkin lymphoma (NHL).

As a fully integrated leader in genome editing and allogeneic CAR-T cell research, we maintain complete end-to-end control over our manufacturing process. This vertical integration ensures quality across the board:

• Paris, France: Production of starting materials

• Raleigh, NC (USA): Manufacturing of the finished CAR-T products

We have established powerful collaborations with industry leaders, including AstraZeneca and Allogene Therapeutics, to accelerate the development of product candidates across oncology, immunology, and rare diseases.

Cellectis headquarters are in Paris, France, with additional locations in New York, New York and Raleigh, North Carolina. Cellectis is listed on the Nasdaq Global Market (ticker: CLLS) and on Euronext Growth (ticker: ALCLS).

To find out more about us, visit our website: www.cellectis.com. To learn more about our community guidelines, visit: http://www.cellectis.com/en/social-media-guidelines/

Follow our other social media account on X.

TALEN® is a registered trademark owned by the Cellectis Group.